UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________. Commission File Number: 001-40800 TYRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1476348 ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) Unaudited financial statements for H1 2022 reflect decreased assets, increased liabilities, and significant operating losses from higher R&D and G&A expenses [Balance Sheets](index=3&type=section&id=Balance%20Sheets) As of June 30, 2022, total assets decreased to **$287.1 million**, while liabilities increased and equity decreased, reflecting the period's net loss Balance Sheet Summary (in thousands) | Balance Sheet Items | June 30, 2022 (unaudited) | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $275,107 | $302,182 | | Total current assets | $277,299 | $304,057 | | Total assets | $287,118 | $306,701 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $5,455 | $3,616 | | Total liabilities | $8,265 | $4,964 | | Accumulated deficit | $(70,292) | $(40,371) | | Total stockholders' equity | $278,853 | $301,737 | [Statements of Operations and Comprehensive Loss](index=4&type=section&id=Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss significantly increased to **$29.9 million** for H1 2022, driven by substantial rises in research and development and general and administrative expenses Operating Results Summary (in thousands, except per share data) | Metric | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $12,047 | $4,381 | $21,692 | $7,902 | | General and administrative | $3,381 | $1,127 | $8,570 | $1,816 | | Total operating expenses | $15,428 | $5,508 | $30,262 | $9,718 | | Loss from operations | $(15,428) | $(5,508) | $(30,262) | $(9,718) | | Net loss | $(15,095) | $(5,512) | $(29,921) | $(9,721) | | Net loss per share | $(0.36) | $(2.43) | $(0.72) | $(4.54) | [Statements of Cash Flows](index=6&type=section&id=Statements%20of%20Cash%20Flows) Net cash used in operating activities significantly increased to **$26.1 million** for H1 2022, while financing cash flow decreased, resulting in a **$26.3 million** net cash decrease Cash Flow Summary (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(26,093) | $(9,139) | | Net cash used in investing activities | $(490) | $(300) | | Net cash provided by financing activities | $265 | $129,419 | | Net cash (decrease) increase | $(26,318) | $119,980 | [Notes to Financial Statements](index=7&type=section&id=Notes%20to%20Financial%20Statements) Notes detail the company's precision oncology focus, IPO proceeds of **$181.2 million**, management's liquidity assessment, stock-based compensation, and new lease agreements - The company is a precision oncology firm focused on developing therapies to overcome therapy resistance in cancer patients[18](index=18&type=chunk) - Management believes it has sufficient working capital to fund operations through at least the next twelve months from the report's issuance date[24](index=24&type=chunk) - In September 2021, upon completing its IPO, all convertible preferred stock was converted into **26,228,089** shares of common stock[39](index=39&type=chunk) - In March 2022, the company entered into an expansion lease for additional office and laboratory space, with projected lease payments of **$5.5 million** over a **120-month** term starting in Q2 2023[57](index=57&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=14&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's oncology pipeline, including FDA clearance for TYRA-300, significant increases in operating expenses, and liquidity sufficient to fund operations through at least 2024 - The company is a precision oncology company focused on developing therapies to overcome tumor resistance, with lead candidates TYRA-300 (FGFR3 inhibitor) and TYRA-200 (FGFR2 inhibitor)[64](index=64&type=chunk) - An Investigational New Drug (IND) application for TYRA-300 was submitted in June 2022, and the company received FDA clearance in July 2022 to proceed with its Phase 1/2 clinical study (SURF301)[64](index=64&type=chunk) - The company expects to continue incurring significant expenses and operating losses as it advances its product candidates through clinical trials and expands its pipeline[67](index=67&type=chunk)[72](index=72&type=chunk) - Based on the current operating plan, existing cash and cash equivalents of **$275.1 million** are expected to be sufficient to fund operations and capital expenditures through at least 2024[68](index=68&type=chunk)[95](index=95&type=chunk) [Results of Operations](index=17&type=section&id=Results%20of%20Operations) Operating expenses sharply increased for H1 2022, with R&D rising to **$21.7 million** due to program advancement and G&A increasing to **$8.6 million** from higher personnel and public company costs R&D Expenses by Program (Six Months Ended June 30, in thousands) | Program | 2022 | 2021 | | :--- | :--- | :--- | | TYRA-300 | $5,352 | $2,818 | | TYRA-200 | $2,864 | $1,391 | | FGFR3 ACH | $1,392 | $— | | RET | $2,589 | $817 | | FGFR4 | $1,084 | $356 | | Unallocated & Personnel | $7,941 | $2,513 | | **Total R&D Expense** | **$21,692** | **$7,902** | - The increase in R&D expenses for the six months ended June 30, 2022 was primarily due to advancing TYRA-300 and TYRA-200, including **$4.7 million** in higher personnel-related costs (of which **$2.8 million** was non-cash stock-based compensation)[84](index=84&type=chunk) - The increase in G&A expenses for the six months ended June 30, 2022 was mainly due to a **$4.5 million** increase in personnel-related expenses (including **$3.3 million** in non-cash stock-based compensation) and higher professional fees and operating costs[86](index=86&type=chunk) [Liquidity and Capital Resources](index=19&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity is primarily from **$181.2 million** IPO proceeds, with **$275.1 million** cash as of June 30, 2022, expected to fund operations through at least 2024, though future capital may be required - The company completed its IPO on September 17, 2021, raising net proceeds of approximately **$181.2 million**[87](index=87&type=chunk) Summary of Cash Flows (Six Months Ended June 30, in thousands) | Category | 2022 | 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(26,093) | $(9,139) | | Net cash used in investing activities | $(490) | $(300) | | Net cash provided by financing activities | $265 | $129,419 | - Future funding requirements will depend on many factors, including the costs and timing of clinical trials, manufacturing, and regulatory reviews[96](index=96&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=21&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes to market risk exposures, including interest rate, foreign currency, and inflation risks, have occurred since the 2021 Annual Report disclosures - As of June 30, 2022, there were no material changes to the company's market risk exposures from those discussed in the 2021 Annual Report[102](index=102&type=chunk) [Controls and Procedures](index=22&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2022, with internal control over financial reporting evaluation deferred until year-end 2022 - Management concluded that as of the end of the quarter, the company's disclosure controls and procedures were effective[105](index=105&type=chunk) - As a newly public company, management is not yet required to evaluate the effectiveness of internal control over financial reporting until the Annual Report for the year ending December 31, 2022[106](index=106&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=23&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently subject to any material legal proceedings - The company is not currently a party to any material legal proceedings[109](index=109&type=chunk) [Risk Factors](index=23&type=section&id=Item%201A.%20Risk%20Factors) No material changes have occurred to the risk factors previously disclosed in the company's 2021 Annual Report on Form 10-K - No material changes have occurred to the risk factors disclosed in the 2021 Annual Report[110](index=110&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=23&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities occurred, and the **$181.2 million** net IPO proceeds' planned use remains materially unchanged - The company's IPO in September 2021 generated net proceeds of approximately **$181.2 million** after deducting underwriting discounts and offering costs[112](index=112&type=chunk) - There has been no material change in the planned use of proceeds from the IPO as described in the final prospectus[113](index=113&type=chunk) [Exhibits](index=24&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including corporate governance documents and CEO/CFO certifications - The report includes a list of exhibits filed, such as the CEO and CFO certifications required under the Sarbanes-Oxley Act of 2002[118](index=118&type=chunk)

TYRA 1 Targeting acquired resistance in oncology with purpose-built drugs May 2022 Disclaimers THIS PRESENTATION IS MADE PURSUANT TO SECTION 5(D) OF THE SECURITIES ACT OF 1933, as amended (the "Act"), and is intended solely for investors that are qualified institutional buyers or institutional accredited investors solely for the purposes of familiarizing such investors with Tyra Biosciences, Inc. (the "Company," "Tyra," "we" or "us") and determining whether such investors might have an interest in a securit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________. Commission File Number: 001-40800 TYRA BIOSCIENCES, INC. (Address of principal executive offices) (Zip Code) Delaware 83-1476348 (I.R.S. ...

1 Targeting acquired resistance in oncology with purpose-built drugs March 2022 Disclaimers THIS PRESENTATION IS MADE PURSUANT TO SECTION 5(D) OF THE SECURITIES ACT OF 1933, as amended (the "Act"), and is intended solely for investors that are qualified institutional buyers or institutional accredited investors solely for the purposes of familiarizing such investors with Tyra Biosciences, Inc. (the "Company," "Tyra," "we" or "us") and determining whether such investors might have an interest in a securities ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR Commission File Number 001-40800 TYRA BIOSCIENCES, INC. (Exact name of Registrant as specified in its Charter) Delaware 83-1476348 (State or other jurisdiction of incorporation or organization) 2656 State Street Carlsbad, California 92008 (Address of principal executive offices) (Zip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________. Commission File Number: 001-40800 TYRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1476348 ...